, Columnist
Celgene's Deal Won't Move the Dial
A small bid for a cast-off drug won't bolster shaken confidence.
This article is for subscribers only.
Last year was solid for the biotech sector generally -- but shaky for industry bellwether Celgene Corp.
The company will have a chance, as it kicks off JPMorgan Chase & Co.'s annual biopharma confab this week, to give investors reason to hope 2018 will be different.